Shenyang Xingqi PharmaceuticalLtd Crecimiento futuro

Future controles de criterios 6/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Shenyang Xingqi PharmaceuticalLtd de 32.8% y 22.6% por año respectivamente. Se prevé que el BPA crezca en un 32.9% al año. Se espera que la rentabilidad financiera sea de 22.1% en 3 años.

Información clave

32.8%

Tasa de crecimiento de los beneficios

32.9%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	18.8%
Tasa de crecimiento de los ingresos	22.6%
Rentabilidad financiera futura	22.1%
Cobertura de analistas	Low
Última actualización	23 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) P/E Is Still On The Mark Following 49% Share Price Bounce

Oct 23

Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) Stocks Pounded By 30% But Not Lagging Market On Growth Or Pricing

Sep 08

With EPS Growth And More, Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Makes An Interesting Case

Aug 19

What You Can Learn From Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) P/S After Its 27% Share Price Crash

Jul 24

Does Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Have A Healthy Balance Sheet?

Jun 28

Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Is Increasing Its Dividend To CN¥3.00

May 21

After Leaping 31% Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) Shares Are Not Flying Under The Radar

May 10

We Ran A Stock Scan For Earnings Growth And Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Passed With Ease

May 07

Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) Looks Just Right With A 26% Price Jump

Mar 15

Previsiones de crecimiento de beneficios e ingresos

SZSE:300573 - Estimaciones futuras de los analistas y datos financieros pasados (CNY Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	3,082	768	N/A	1,474	1
12/31/2025	2,680	669	N/A	1,171	1
12/31/2024	2,117	449	N/A	867	1
9/30/2024	1,802	348	270	447	N/A
6/30/2024	1,674	322	211	400	N/A
3/31/2024	1,531	255	153	343	N/A
12/31/2023	1,468	240	56	318	N/A
9/30/2023	1,350	191	8	254	N/A
6/30/2023	1,335	179	27	256	N/A
3/31/2023	1,234	157	-103	241	N/A
1/1/2023	1,250	212	-13	286	N/A
9/30/2022	1,262	241	90	378	N/A
6/30/2022	1,166	235	80	362	N/A
3/31/2022	1,123	236	234	363	N/A
1/1/2022	1,028	195	212	307	N/A
9/30/2021	990	190	156	243	N/A
6/30/2021	914	153	92	186	N/A
3/31/2021	813	132	68	167	N/A
12/31/2020	689	88	14	122	N/A
9/30/2020	602	61	0	81	N/A
6/30/2020	528	45	-28	51	N/A
3/31/2020	514	24	-21	64	N/A
12/31/2019	542	36	4	74	N/A
9/30/2019	504	29	-9	62	N/A
6/30/2019	480	21	-13	45	N/A
3/31/2019	453	17	4	48	N/A
12/31/2018	431	14	-1	44	N/A
9/30/2018	416	11	8	58	N/A
6/30/2018	379	9	N/A	63	N/A
3/31/2018	362	28	N/A	28	N/A
12/31/2017	360	39	N/A	33	N/A
9/30/2017	361	51	N/A	11	N/A
6/30/2017	356	51	N/A	10	N/A
3/31/2017	347	55	N/A	32	N/A
12/31/2016	339	54	N/A	28	N/A
12/31/2015	287	22	N/A	21	N/A
12/31/2014	255	31	N/A	13	N/A
12/31/2013	219	46	N/A	8	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (32.8% al año) de 300573 es superior a la tasa de ahorro (2.8%).

Beneficios vs. Mercado: Se prevé que los beneficios (32.8% al año) de 300573 crezcan más rápidamente que el mercado CN (26.2% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de 300573 crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (22.6% al año) de 300573 crezcan más rápidamente que los del mercado CN (13.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (22.6% al año) de 300573 crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de 300573 sea alta dentro de 3 años (22.1%)

Shenyang Xingqi PharmaceuticalLtd Crecimiento futuro

Future controles de criterios 6/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.70 (vs CN¥0.54 in 3Q 2023)

Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) P/E Is Still On The Mark Following 49% Share Price Bounce

Investor sentiment deteriorates as stock falls 28%

Shenyang Xingqi Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 29, 2024

New major risk - Share price stability

Investor sentiment improves as stock rises 17%

Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) Stocks Pounded By 30% But Not Lagging Market On Growth Or Pricing

Investor sentiment deteriorates as stock falls 19%

Shenyang Xingqi Pharmaceutical Co.,Ltd. Proposes Profit Distribution for First Half of 2024

Second quarter 2024 earnings released: EPS: CN¥0.77 (vs CN¥0.39 in 2Q 2023)

With EPS Growth And More, Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Makes An Interesting Case

High number of new directors

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 19%

What You Can Learn From Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) P/S After Its 27% Share Price Crash

Shenyang Xingqi Pharmaceutical Co.,Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Does Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Have A Healthy Balance Sheet?

Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Is Increasing Its Dividend To CN¥3.00

Dividend of CN¥3.00 announced

Shenyang Xingqi Pharmaceutical Co.,Ltd. Announces Cash Dividend for 2023, Payable May 22, 2024

After Leaping 31% Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) Shares Are Not Flying Under The Radar

We Ran A Stock Scan For Earnings Growth And Shenyang Xingqi PharmaceuticalLtd (SZSE:300573) Passed With Ease

First quarter 2024 earnings released: EPS: CN¥0.28 (vs CN¥0.16 in 1Q 2023)

Shenyang Xingqi Pharmaceutical Co.,Ltd., Annual General Meeting, May 13, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Shenyang Xingqi Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Shenyang Xingqi Pharmaceutical Co.,Ltd. (SZSE:300573) Looks Just Right With A 26% Price Jump

Shenyang Xingqi Pharmaceutical Co.,Ltd. Approves Board Elections

Shenyang Xingqi Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 19, 2024

Third quarter 2023 earnings released: EPS: CN¥0.76 (vs CN¥0.66 in 3Q 2022)

New major risk - Share price stability

Shenyang Xingqi Pharmaceutical Co.,Ltd. to Report Q3, 2023 Results on Oct 24, 2023

Shenyang Xingqi Pharmaceutical Co.,Ltd. Announces Interim Dividend on A Shares for the Year 2023, Payable on 22 September 2023

Shenyang Xingqi Pharmaceutical Co.,Ltd Approves Cash Interim Profit Distribution Plan for 2023

High number of new directors

Shenyang Xingqi Pharmaceutical Co.,Ltd. Proposes Interim Dividend for the First Half of 2023

Investor sentiment improves as stock rises 17%

Full year 2022 earnings released: EPS: CN¥2.41 (vs CN¥2.39 in FY 2021)

Less than half of directors are independent

Investor sentiment deteriorates as stock falls 17%

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Now 21% undervalued

Third quarter 2022 earnings released: EPS: CN¥0.93 (vs CN¥0.90 in 3Q 2021)

Shenyang Xingqi Pharmaceutical Co.,Ltd Announces Interim Dividend on A Shares for the Year 2021, Payable on September 23, 2022

Shenyang Xingqi Pharmaceutical Co.,Ltd Approves Interim Cash Dividend for 2022

Shenyang Xingqi Pharmaceutical Announces Profit Distribution Proposal for the First Half of 2022

Second quarter 2022 earnings released: EPS: CN¥0.53 (vs CN¥0.59 in 2Q 2021)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Shenyang Xingqi Pharmaceutical Co.,Ltd Announces 2021 Final Profit Distribution Plan to Be Implemented on A Shares, Payable on 20 May 2022

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: CN¥0.84 (vs CN¥0.40 in 1Q 2021)

Shenyang Xingqi Pharmaceutical Co.,Ltd Proposes Final Cash Dividend for the Year 2021

Full year 2021 earnings released: EPS: CN¥2.39 (vs CN¥1.09 in FY 2020)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.90 (vs CN¥0.47 in 3Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.59 (vs CN¥0.32 in 2Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Shenyang Xingqi Pharmaceutical Co., Ltd. Announces Final Cash Dividend for the Year 2020, Payable on 21 May 2021

Full year 2020 earnings released: EPS CN¥1.09 (vs CN¥0.45 in FY 2019)

Shenyang Xingqi Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Apr 20, 2021

New 90-day low: CN¥93.15

Shenyang Xingqi Pharmaceutical Co., Ltd. Approves Directorate Elections

New 90-day low: CN¥107

New 90-day low: CN¥124

Third quarter earnings released

New 90-day low: CN¥129

New 90-day low - CN¥136

Shenyang Xingqi Pharmaceutical Co.,Ltd announced that it expects to receive CNY 800 million in funding